Results 141 to 150 of about 2,330 (177)
Some of the next articles are maybe not open access.
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
Journal of Cystic FibrosisCystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor/tezacaftor/ivacaftor (ETI), significantly improve outcomes and quality of life for people with cystic fibrosis (CF). However, little is known about how lung transplant recipients (LTRs) perceive the use of ETI.
Dave Young +9 more
openaire +2 more sources
Efficacy of Elexacaftor–Tezacaftor–Ivacaftor on chronic rhinosinusitis in cystic fibrosis
American Journal of OtolaryngologyOur work aims to add evidence on the effectiveness of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.We conducted an observational retrospective cohort study at the Cystic Fibrosis Center of a tertiary care hospital to investigate the effect of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis ...
Di Gioia, Stefano +6 more
openaire +3 more sources
Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Journal of Cystic FibrosisHighly effective modulators of the CFTR channel have been demonstrated to dramatically impact disease progression and outcome. However, real-world data indicates that the magnitude of the clinical benefit is not equal among all patients receiving the treatment.
Gianfranco Alicandro +8 more
openaire +2 more sources
Effects of elexacaftor–tezacaftor–ivacaftor discontinuation in cystic fibrosis
Respiratory Medicine and Research, 2022Georgia Mitropoulou +5 more
openaire +2 more sources
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Pediatric PulmonologyAbstract Introduction The triple combination of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved the outcome of people with Cystic Fibrosis (pwCF) with at least one F508del mutation.
Valentina Fainardi +9 more
openaire +3 more sources
P151 Pregnancies with elexacaftor/tezacaftor/ivacaftor in Argentina
Journal of Cystic Fibrosis, 2023E. Baran, L. Osken, N. Bergas Gimbernat
openaire +1 more source
Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant
Current Opinion in Pulmonary MedicinePurpose of review In 2019, the United States Food and Drug Administration approved a breakthrough therapeutic for cystic fibrosis, elexacaftor–tezacaftor–ivacaftor (ETI), because of its profound effect on lung function in large phase III clinical trials.
Siddhartha G, Kapnadak +1 more
openaire +2 more sources
Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Pediatric Pulmonology, 2021Ashlee Anderson +4 more
openaire +2 more sources